• Latest
  • Trending
  • All
  • Featured Urology
  • Female Urology
  • Urologic Oncology
  • What is Urology?
  • Pediatric Urology
  • Urology

Scientists develop ‘barcode’ blood test for aggressive prostate cancer

September 8, 2020
Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

November 14, 2022
New treatment can more than double life expectancy for people with prostate cancer: doctor

New treatment can more than double life expectancy for people with prostate cancer

November 14, 2022
Study finds that use of yoga app can reduce urinary incontinence

Study finds that use of yoga app can reduce urinary incontinence

November 9, 2022
Urinary Incontinence: Types and Treatments

Urinary Incontinence: Types and Treatments

November 9, 2022
Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

November 4, 2022
Can Erectile Dysfunction Drugs Reduce Dementia Risk?

Can Erectile Dysfunction Drugs Reduce Dementia Risk?

November 4, 2022
New PSA test examines protein structures to detect prostate cancers

New PSA test examines protein structures to detect prostate cancers

November 2, 2022
A better way to image metastatic prostate cancer

A better way to image metastatic prostate cancer

November 2, 2022
Newly discovered protein may protect kidney cells from injury

Newly discovered protein may protect kidney cells from injury

November 2, 2022
A person’s diet, acidity of urine may affect susceptibility to UTIs

A person’s diet, acidity of urine may affect susceptibility to UTIs

November 2, 2022
Award-winning agent developed for prostate cancer diagnosis and treatment

Award-winning agent developed for prostate cancer diagnosis and treatment

November 2, 2022
New treatment for polycystic kidney disease

New treatment for polycystic kidney disease

November 2, 2022
Saturday, November 19, 2022
Urology Today
  • Home
  • Featured Urology
    Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

    Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

    Study finds that use of yoga app can reduce urinary incontinence

    Study finds that use of yoga app can reduce urinary incontinence

    Urinary Incontinence: Types and Treatments

    Urinary Incontinence: Types and Treatments

    Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

    Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

    Kidney failure impacts survival of sepsis patients

    Kidney failure impacts survival of sepsis patients

    Urine-based test improves on PSA for detecting prostate cancer

    Urine-based test improves on PSA for detecting prostate cancer

    Unemployment linked to rise in prostate cancer deaths

    Unemployment linked to rise in prostate cancer deaths

    Unemployment linked to rise in prostate cancer deaths

    Advanced viral gene therapy eradicates prostate cancer in preclinical experiments

    prostate cancer

    Recurrence of prostate cancer detected earlier with innovative PSMA-ligand PET/CT

    Two major studies strengthen case for prostate cancer drug before chemotherapy

    Two major studies strengthen case for prostate cancer drug before chemotherapy

    Trending Tags

    • Donald Trump
    • Future of News
    • Climate Change
    • Market Stories
    • Election Results
    • Flat Earth
  • Lifestyle
    • All
    • Female Urology
    • Male Urology
    • Pediatric Urology
    Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

    Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

    Study finds that use of yoga app can reduce urinary incontinence

    Study finds that use of yoga app can reduce urinary incontinence

    Urinary Incontinence: Types and Treatments

    Urinary Incontinence: Types and Treatments

    New PSA test examines protein structures to detect prostate cancers

    New PSA test examines protein structures to detect prostate cancers

    A better way to image metastatic prostate cancer

    A better way to image metastatic prostate cancer

    Award-winning agent developed for prostate cancer diagnosis and treatment

    Award-winning agent developed for prostate cancer diagnosis and treatment

    New treatment for polycystic kidney disease

    New treatment for polycystic kidney disease

    Urine-based test improves on PSA for detecting prostate cancer

    Urine-based test improves on PSA for detecting prostate cancer

    Unemployment linked to rise in prostate cancer deaths

    Advanced viral gene therapy eradicates prostate cancer in preclinical experiments

    Two major studies strengthen case for prostate cancer drug before chemotherapy

    Two major studies strengthen case for prostate cancer drug before chemotherapy

    Trending Tags

    • Golden Globes
    • Mr. Robot
    • MotoGP 2017
    • Climate Change
    • Flat Earth
No Result
View All Result
Urology Today
No Result
View All Result
Home Urology / Nephrology News

Scientists develop ‘barcode’ blood test for aggressive prostate cancer

by Urology Today
September 8, 2020
in Urology / Nephrology News
0
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

Scientists have designed a blood test that reads genetic changes like a barcode – and can pick out aggressive prostate cancers by their particular pattern of gene activity.

A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust found reading the pattern of genes switched on and off in blood cells could accurately detect which advanced prostate cancers had the worst survival.

And the researchers believe the blood test could eventually be used alongside the existing PSA test at diagnosis to select patients who need immediate treatment.

The test, described in The Lancet Oncology today (Tuesday 9 October), is unique because it assesses changes in the pattern of gene activity in blood cells triggered by a tumour elsewhere in the body.

Study senior author Professor Johann de Bono, leader of the prostate cancer targeted therapy team at The Institute of Cancer Research, London, and honorary consultant at The Royal Marsden NHS Foundation Trust, said: “Prostate cancer is a very diverse disease – some people live with it for years without symptoms but for others it can be aggressive and life-threatening – so it’s vital we develop reliable tests to tell the different types apart.

“We’ve shown it is possible to learn more about prostate cancers by the signs they leave in the blood, allowing us to develop a test that is potentially more accurate than those available now and easier for patients than taking a biopsy. Our test reads the pattern of genetic activity like a barcode, picking up signs that a patient is likely to have a more aggressive cancer. Doctors should then be able to adjust the treatment they give accordingly.”

Researchers scanned all the genes present in blood samples from 100 patients with prostate cancer at the ICR’s and The Royal Marsden’s joint Drug Development Unit in London and The Beatson West of Scotland Cancer Centre in Glasgow. They included 69 patients with advanced cancer and 31 control patients thought to have low-risk, early-stage cancer, who were being managed by active surveillance.

Using statistical modelling, they divided the patients into four groups reflecting their pattern of gene activity – the barcode. When they reviewed all the patients’ progress after almost two-and-a-half years, they found patients in one group had survived for significantly less time than patients in the others. Further modelling identified nine key active genes that were shared by all patients in the group.

They confirmed the results in another 70 US patients with advanced cancer, showing that just these nine genes could be used to accurately identify those who ultimately survived for a shorter time – 9.2 months compared with 21.6 months for patients without the gene pattern. The genes included a number involved in the immune system – suggesting the immune system was suppressed in patients whose cancers were spreading around the body.

Professor Alan Ashworth, chief executive of The Institute of Cancer Research, said: “Whether particular genes are active or not is an important clue in identifying patients with a poor prognosis. This latest study shows that it is possible to read these patterns of gene activity like a barcode, allowing scientists to spot cancers that are likely to be more aggressive.”

Professor Martin Gore, medical director at The Royal Marsden, said: “Personalised medicine is the future of cancer treatment. This blood test, which reads genetic changes in prostate cancer providing a prediction of how aggressive the cancer might be, is an important development, allowing us to better tailor treatment to suit each individual.”

###

The study received funding from AstraZeneca, Prostate Cancer UK (formerly the Prostate Cancer Charity) and the Prostate Cancer Foundation, while the Drug Development Unit also receives funding from Cancer Research UK and the Experimental Cancer Medicine Centre network.

Media Contact: ICR Science Communications Manager Jane Bunce on 0207
153 5106 or 07 721 747 900

Notes to editors:

“Prognostic value of blood mRNA expression signatures in castration resistant prostate cancer: a prospective two-stage study” will publish in The Lancet Oncology on 9 October 2012.

The scientists initially plan to assess the test as part of a large-scale international trial of a new prostate cancer drug in patients with advanced cancer. They also hope to assess the test in patients with earlier-stage disease, using either the existing nine-gene pattern or using the same technique to find another set of genes.

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR’s mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

The Royal Marsden NHS Foundation Trust

The Royal Marsden opened its doors in 1851 as the world’s first hospital dedicated to cancer diagnosis, treatment, research and education. Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 44,000 patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.

Since 2004, the hospital’s charity, The Royal Marsden Cancer Charity, has helped raise over £50 million to build theatres, diagnostic centres, and drug development units.

Share196Tweet123Share49
Urology Today

Urology Today

  • Trending
  • Comments
  • Latest

Urethral pressure profilometry

September 8, 2020
Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer

November 4, 2022
Embryogenesis -Paediatric Urology

Embryogenesis -Paediatric Urology

November 2, 2022

Genetic basis of genitourinary malformations

0
Embryogenesis -Paediatric Urology

Embryogenesis -Paediatric Urology

0
Upper urinary tract

Upper urinary tract

0
Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

Yoga for Prostate Cancer: Best Yoga exercises to combat prostate growth in men

November 14, 2022
New treatment can more than double life expectancy for people with prostate cancer: doctor

New treatment can more than double life expectancy for people with prostate cancer

November 14, 2022
Study finds that use of yoga app can reduce urinary incontinence

Study finds that use of yoga app can reduce urinary incontinence

November 9, 2022
Urology Today

Copyright © 2022 Urology Today.

Navigate Site

  • About
  • Advertise
  • Privacy & Policy
  • Contact

Follow Us

No Result
View All Result
  • Home
  • Featured Urology
    • Urologic Oncology
    • Female Urology
    • Pediatric Urology
    • What is Urology?
  • Lifestyle

Copyright © 2022 Urology Today.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In